在本研究中，对肝细胞癌（HCC）数据集进行生物信息学分析，分析扶正化瘀（FZHY）胶囊对二乙基亚硝胺诱导的HCC进展的保肝作用。确定了八个细胞簇，并且 FZHY 胶囊的化合物丹参酮 IIA、花生四烯酸和槲皮素通过调节 PLAU 和 IGFBP3 的表达来抑制 HCC 进展相关的纤维化。结合FZHY胶囊对肝功能障碍以及PLAU和IGFBP3表达的改善作用，我们的研究证实了FZHY胶囊通过调节PLAU和IGFBP3的表达来抑制纤维化相关HCC进展的作用。

In the current study, bioinformatics analysis of the hepatocellular carcinoma (HCC) dataset was conducted with the hepatoprotective effect of the Fuzheng Huayu (FZHY) capsule against the diethylnitrosamine-induced HCC progression analyzed. Eight cell clusters were defined and tanshinone IIA, arachidonic acid, and quercetin, compounds of the FZHY capsule, inhibit HCC progression-related fibrosis by regulating the expression of PLAU and IGFBP3. Combined with the ameliorative effect of the FZHY capsule against liver dysfunctions and expression of PLAU and IGFBP3, our study confirmed the effect of the FZHY capsule on inhibiting the fibrosis-associated HCC progression via regulating the expression of PLAU and IGFBP3.